This federal contract award was issued by the Department of Veterans Affairs (VA) to Ardelyx, Inc., a for-profit pharmaceutical company, for the supply of XPHOZAH (tenapanor), a medication used to treat hyperphosphatemia in chronic kidney disease patients on dialysis. The contract, a $34,284.07 firm-fixed-price delivery order, was awarded on October 1, 2024 under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) with a completion date of April 1, 2025. Ardelyx holds multiple Federal Supply Schedule contracts and a $32,500,000 Blanket Purchase Agreement (BPA) specifically for XPHOZAH, enabling it to serve as a key supplier of this specialized medication to VA medical centers nationwide. The contract does not have a socioeconomic set-aside designation, indicating that Ardelyx competes in the open market for these VA pharmaceutical supply contracts.
Generated 11/27/24, 9:29 AM